Novartis MS Pill Gets OK in Russia, Others May Follow

Novartis AG’s multiple sclerosis pill Gilenia is set to be launched in Russia early next year after health authorities there approved the novel drug, increasing its chances to pass regulatory hurdles in the U.S. and Europe and allowing the Swiss pharma giant to take a decisive lead over competitors in this market segment.
Morningstar